{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:22:37Z","timestamp":1790871757161,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) presents distinct diagnostic and therapeutic challenges because of its rarity, anatomic constraints, frequent understaging at biopsy, and risk of systemic recurrence after radical nephroureterectomy. Current perioperative management is driven primarily by clinicopathologic risk factors, which may be insufficient to identify occult molecular residual disease (MRD) or to determine which patients are most likely to benefit from systemic therapy. This narrative review summarizes available evidence on circulating tumor DNA (ctDNA) in UTUC and related urothelial carcinoma settings, classifies the level of evidence supporting each application, and proposes a research framework for prospective evaluation. The strongest UTUC-specific evidence supports ctDNA as a prognostic biomarker associated with recurrence risk, whereas predictive validity for selecting chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, targeted therapy, or surveillance intensity remains unproven. Evidence from muscle-invasive bladder cancer, including ctDNA-correlative and ctDNA-guided perioperative trials, provides biologic rationale but should not be directly translated into routine UTUC care without disease-specific validation. We outline key implementation questions, including target population, assay selection, timing, false-positive and false-negative results, lead-time bias, and integration of plasma ctDNA with utDNA. Prospective UTUC-specific trials are needed to determine whether ctDNA-guided perioperative strategies improve survival, reduce unnecessary toxicity, and are cost-effective.<\/jats:p>","DOI":"10.3390\/cancers18101651","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:12:41Z","timestamp":1779268361000},"page":"1651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating Tumor DNA in Upper Tract Urothelial Carcinoma: A Framework for Precision Perioperative Management"],"prefix":"10.3390","volume":"18","author":[{"given":"Amulya","family":"Prakash","sequence":"first","affiliation":[{"name":"Penn State Cancer Institute, 400 University Dr., Hershey, PA 17033, USA"},{"name":"Department of Hematology-Oncology, Penn State College of Medicine, 700 HMC Crescent Rd., Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriani","family":"Cherico","sequence":"additional","affiliation":[{"name":"Penn State Cancer Institute, 400 University Dr., Hershey, PA 17033, USA"},{"name":"Department of Hematology-Oncology, Penn State College of Medicine, 700 HMC Crescent Rd., Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adanma","family":"Ayanambakkam","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-2111","authenticated-orcid":false,"given":"Hyma Vani","family":"Polimera","sequence":"additional","affiliation":[{"name":"Penn State Cancer Institute, 400 University Dr., Hershey, PA 17033, USA"},{"name":"Department of Hematology-Oncology, Penn State College of Medicine, 700 HMC Crescent Rd., Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel use of circulating tumor DNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma","volume":"85","author":"Huelster","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euros.2022.05.004","article-title":"Site-specific risk stratification models for postoperative recurrence and survival prediction in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy: Better stratification for adjuvant therapy","volume":"41","author":"Miyake","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"ref_5","first-page":"1","article-title":"Management of low-grade upper tract urothelial carcinoma: An unmet need","volume":"22","author":"Raman","year":"2020","journal-title":"Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO-25-00179","article-title":"Safety and efficacy of neoadjuvant durvalumab plus gemcitabine\/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: The iNDUCT-GETUG V08 trial","volume":"43","author":"Chevallier","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1395","DOI":"10.1002\/onco.13839","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Carbunaru, S., Rich, J.M., and Murray, K.S. (2025). Adjuvant chemotherapy and immunotherapy in upper tract urothelial carcinoma: Where do we stand?. Cancers, 17.","DOI":"10.3390\/cancers17193226"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/cas.15334","article-title":"Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma","volume":"113","author":"Nakano","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-23-0513","article-title":"Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/s41591-025-03802-8","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial","volume":"31","author":"Galsky","year":"2025","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"Perioperative enfortumab vedotin plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer: LBA2, phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_17","first-page":"LBA630","article-title":"Randomized, open-label, phase 3 KEYNOTE-B15 study: Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"44","author":"Hoimes","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: A 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_19","unstructured":"Alliance for Clinical Trials in Oncology (2024). MODERN: An Integrated Phase II\/III and Phase III Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer, Alliance for Clinical Trials in Oncology. ClinicalTrials.gov identifier: NCT05987241."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: Results from the TOMBOLA trial","volume":"37","author":"Nordentoft","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Herrero, E.S., Serna-Blasco, R., Somoza, \u00c1., Mart\u00ednez-Garc\u00eda, M., Garc\u00eda-Pav\u00eda, P., Jim\u00e9nez, M., S\u00e1nchez-Carpintero, A.B., D\u00edaz-Lagares, A., L\u00f3pez-Rios, F., and de la Orden, V. (2022). Circulating tumor DNA as a cancer biomarker: An overview of biological features and factors that may impact ctDNA analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.943253"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2414558","DOI":"10.1002\/advs.202414558","article-title":"Patient-derived bladder cancer organoids as a valuable tool for understanding tumor biology and developing personalized treatment","volume":"12","author":"Zhao","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e006284","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA mutations in urine cell-free DNA from bladder cancer patients","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2533449123","DOI":"10.1073\/pnas.2533449123","article-title":"Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer","volume":"123","author":"Galsky","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: Disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_32","first-page":"eaar5215","article-title":"Non-invasive detection of urothelial cancer through urine DNA analysis","volume":"10","author":"Springer","year":"2018","journal-title":"Sci. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:38:55Z","timestamp":1779269935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101651"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101651","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}